Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Allocation to vitamin D for 12-months was associated with 2-fold higher plasma levels of 25-hydroxy-vitamin D (25[OH]D, 4000 IU regimen), but had no significant effect on whole-blood gene expression (FDR < 5%) or on plasma levels of cytokines compared with placebo.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Double-blind reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial

Source: Article title.

In the Biochemical Efficacy and Safety Trial of Vitamin D (BEST-D), a double-blind, placebo-controlled, dose-finding, randomized clinical trial, 305 community-dwelling individuals aged over 65 years were randomly allocated to treatment with vitamin D3 4000 IU, 2000 IU or placebo daily for 12 months.

Source: Abstract.

•We carried out molecular analyses in a randomized, placebo-controlled, clinical trial of daily vitamin D supplementation.•Participants were Caucasian, aged >65 years with measurements at baseline and 12 months for placebo, 2000 IU or 4000 IU.•We did not find significant differences in genomic, transcriptomic or cytokines in blood despite large changes in 25(OH)D levels.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial

Randomised controlled trial · EBioMedicine · 2018

Original publication title

Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial

Antonio J. Berlanga-Taylor; Katharine Plant; Andrew Dahl; Evelyn Lau; Michael Hill; David Sims; Andreas Heger; Jonathan Emberson; Jane Armitage; Robert Clarke; Julian C. Knight

© 2018 The Authors

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

We performed a comprehensive functional genomics and molecular analysis of vitamin D supplementation in a randomized, placebo-controlled trial. Although this study was limited to mostly Caucasian individuals aged over 65 years, the results differ from many previous studies and do not support a strong effect of vitamin D on long-term transcriptomic changes in blood or on plasma cytokine levels. The trial demonstrates the feasibility of applying functional genomic and genetic approaches in randomized trials to assess molecular and individual level responses.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Vitamin D deficiency has been associated with multiple diseases, but the causal relevance and underlying processes are not fully understood. Elucidating the mechanisms of action of drug treatments in humans is challenging, but application of functional genomic approaches in randomized trials may afford an opportunity to systematically assess molecular responses.

Source: Background

Abstract: What methods does the paper describe?

In the Biochemical Efficacy and Safety Trial of Vitamin D (BEST-D), a double-blind, placebo-controlled, dose-finding, randomized clinical trial, 305 community-dwelling individuals aged over 65 years were randomly allocated to treatment with vitamin D3 4000 IU, 2000 IU or placebo daily for 12 months. Genome-wide genotypes at baseline, and transcriptome and plasma levels of cytokines (IFN-γ, IL-10, IL-8, IL-6 and TNF-α) at baseline and after 12 months, were measured. The trial had >90% power to detect 1.2-fold changes in gene expression.

Source: Methods

Abstract: Key Result

Supplementation with high-dose vitamin D in older people for 12 months in a randomized, placebo-controlled trial had no significant effect on gene expression or on plasma concentrations of selected cytokines.

Source: Key Result

Abstract: Findings

Allocation to vitamin D for 12-months was associated with 2-fold higher plasma levels of 25-hydroxy-vitamin D (25[OH]D, 4000 IU regimen), but had no significant effect on whole-blood gene expression (FDR < 5%) or on plasma levels of cytokines compared with placebo. In pre-specified analysis, rs7041 (intron variant, GC) had a significant effect on circulating levels of 25(OH)D in the low dose, but not in the placebo or high dose vitamin D regimen. A gene expression quantitative trait locus analysis (eQTL) demonstrated evidence of 31,568 cis-eQTLs (unique SNP-probe pairs) among individuals at baseline and 34,254 after supplementation for 12 months (any dose).

No significant associations involving vitamin D supplementation response eQTLs were found.

Source: Findings

Abstract: Interpretation

We performed a comprehensive functional genomics and molecular analysis of vitamin D supplementation in a randomized, placebo-controlled trial. Although this study was limited to mostly Caucasian individuals aged over 65 years, the results differ from many previous studies and do not support a strong effect of vitamin D on long-term transcriptomic changes in blood or on plasma cytokine levels. The trial demonstrates the feasibility of applying functional genomic and genetic approaches in randomized trials to assess molecular and individual level responses.

Source: Interpretation
Authors’ abstract

Background

Vitamin D deficiency has been associated with multiple diseases, but the causal relevance and underlying processes are not fully understood. Elucidating the mechanisms of action of drug treatments in humans is challenging, but application of functional genomic approaches in randomized trials may afford an opportunity to systematically assess molecular responses.

Methods

In the Biochemical Efficacy and Safety Trial of Vitamin D (BEST-D), a double-blind, placebo-controlled, dose-finding, randomized clinical trial, 305 community-dwelling individuals aged over 65 years were randomly allocated to treatment with vitamin D3 4000 IU, 2000 IU or placebo daily for 12 months. Genome-wide genotypes at baseline, and transcriptome and plasma levels of cytokines (IFN-γ, IL-10, IL-8, IL-6 and TNF-α) at baseline and after 12 months, were measured. The trial had >90% power to detect 1.2-fold changes in gene expression.

Findings

Allocation to vitamin D for 12-months was associated with 2-fold higher plasma levels of 25-hydroxy-vitamin D (25[OH]D, 4000 IU regimen), but had no significant effect on whole-blood gene expression (FDR < 5%) or on plasma levels of cytokines compared with placebo. In pre-specified analysis, rs7041 (intron variant, GC) had a significant effect on circulating levels of 25(OH)D in the low dose, but not in the placebo or high dose vitamin D regimen. A gene expression quantitative trait locus analysis (eQTL) demonstrated evidence of 31,568 cis-eQTLs (unique SNP-probe pairs) among individuals at baseline and 34,254 after supplementation for 12 months (any dose).

No significant associations involving vitamin D supplementation response eQTLs were found.

Interpretation

We performed a comprehensive functional genomics and molecular analysis of vitamin D supplementation in a randomized, placebo-controlled trial. Although this study was limited to mostly Caucasian individuals aged over 65 years, the results differ from many previous studies and do not support a strong effect of vitamin D on long-term transcriptomic changes in blood or on plasma cytokine levels. The trial demonstrates the feasibility of applying functional genomic and genetic approaches in randomized trials to assess molecular and individual level responses.

Key Result

Supplementation with high-dose vitamin D in older people for 12 months in a randomized, placebo-controlled trial had no significant effect on gene expression or on plasma concentrations of selected cytokines.

Trial Registration

SRCTN registry (Number 07034656) and the European Clinical Trials Database (EudraCT Number 2011-005763-24).

Highlights

  • •

    We carried out molecular analyses in a randomized, placebo-controlled, clinical trial of daily vitamin D supplementation.

  • •

    Participants were Caucasian, aged >65 years with measurements at baseline and 12 months for placebo, 2000 IU or 4000 IU.

  • •

    We did not find significant differences in genomic, transcriptomic or cytokines in blood despite large changes in 25(OH)D levels.

Many studies have reported associations of vitamin D deficiency with different diseases, but little is known about the causal relevance of such associations. Genomics technologies can provide important tools for discovery and validation of disease and drug mechanisms in clinical trials, but have not been widely used. Vitamin D is known to have genome-wide effects, but results have mainly come from laboratory models or small studies in humans. Results of previous studies differ, possibly reflecting the complexity of synthesis and metabolism of vitamin D.

In the present study, we used a randomized placebo-controlled trial, but did not observe any significant differences in expression in genes (genome-wide) or on plasma concentrations of selected cytokines in community-dwelling older individuals. Vitamin D is essential for human physiology and undoubtedly has multiple effects. Such effects are likely to vary between cells, tissues, individuals, populations and environmental circumstances. The mechanisms which regulate vitamin D are complex and likely to be robust to such differences. The present study shows that integrating high throughput molecular measurements is feasible in a community-based clinical trial and the results will inform future research investigating the mechanisms of action of vitamin D.

Publication and source details

Original title: Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial

Antonio J. Berlanga-Taylor; Katharine Plant; Andrew Dahl; Evelyn Lau; Michael Hill; David Sims; Andreas Heger; Jonathan Emberson; Jane Armitage; Robert Clarke; Julian C. Knight

EBioMedicine · 2018

⁎ Corresponding author. julian@well.ox.ac.uk© 2018 The Authors2018https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T04:51:22.979329+00:00

DOI: 10.1016/j.ebiom.2018.04.010 · PMC6013786